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C
rohn disease (CD) and 
ulcerative colitis (UC) are 
chronic inflammatory intestinal 
diseases with multifactorial etiologies. 
CD and UC are distinguished both by 
the location and by the nature of the 
inflammation. CD displays a transmural 
discontinuous inflammation, often 
with granulomas, in any part of 
the digestive system (most often 
ileum and/or colon). UC is almost 
exclusively restricted to the colon with 
a continuous superficial mucosal and 
submucosal inflammation. Both CD 
and UC can be further subphenotyped, 
suggesting that there is heterogeneity 
within each disorder. Despite many 
clinical and pathological features 
that distinguish CD and UC, the 
collective term inflammatory bowel 
disease (IBD) is often used for the two 
diseases. Clustering of IBD in families 
without specificity for a given form of 
IBD supports the notion of common 
genetic factors in the etiologies of the 
two conditions. In addition, higher 
concordance rates in monozygotic 
twins than dizygotic twins, particularly 
in CD, points to the importance of 
genes [1]. Recent advances in genetics 
have proven that both CD and UC 
are truly polygenic, but there are also 
strong environmental influences on 
IBD. This notion is first and foremost 
supported by the rapid increase in 
incidence of IBD during the past 50 
years.
Understanding the complex 
interplay between genetic and 
environmental factors that lead to 
IBD is a formidable challenge. Animal 
models have been very helpful in 
this respect, providing fundamental 
insight into the importance of 
immunologic dysregulation and 
intestinal microbiota [2,3]. Animal 
models are continuing to give new 
insights into the pathogenesis of IBD, 
as shown by two recent papers in PLoS 
Medicine [4,5]. Simultaneously, there 
have been remarkable advances in 
the understanding of the genetics of 
human IBD, and the mapping of IBD 
genes is continuously progressing 
[6–8]. The new genetic findings bear 
promise for new and better therapies. 
This translation of basic science into 
the clinic will be much facilitated by 
relevant and good animal models. We 
can thus expect that the new genetic 
findings will set the stage for future 
development of animal models in IBD. 
Animal Models of IBD
Many strains of mice with genetic 
defects in immune regulation develop 
colitis (Figure 1). Such genetic 
defects include targeted deletion of 
receptors for the regulatory cytokines 
transforming growth factor (TGF)-β 
or interleukin (IL)-10, and other 
mutations causing a disruption 
of signaling from these cytokines 
[9]. Specific T cell involvement 
in dysregulation can be shown by 
transfer of a subpopulation of T cells 
(CD4+CD45RB+) to lymphopenic 
hosts, which leads to colitis [10]. It 
was early established that cotransfer 
of CD4+CD25+ T cells could suppress 
colitis development, and the concept 
that FoxP3+ regulatory T (Treg) 
cells play an important general 
anti-inflammatory role is now also 
established in human studies [11]. 
Appropriate barrier function 
of the epithelium is critical to gut 
homeostasis (Figure 1) [12]. An 
early demonstration of this concept 
was the spontaneous intestinal 
inflammation occurring in mice 
with mucosal leakiness caused 
by dominant negative epithelial 
N-cadherin [13]. Although the 
picture in these mice is complicated 
by epithelial proliferation, apoptosis, 
and neoplasms, further support of 
the barrier concept comes from 
the fact that mice lacking the major 
component of intestinal mucus, 
Muc2-/- mice, develop spontaneous 
colitis [14]. Furthermore, mice with 
enterocyte-specific ablation of nuclear 
factor kappa B (NF-κB) activation 
fail to control the luminal microbial 
flora, and inflammation is triggered 
by an exaggerated immune response 
to invading bacteria [15,16]. Other 
defects in innate or adaptive defense, 
or chemical irritation of the colonic 
mucosa, may have similar outcomes. 
For instance, dextran sulfate sodium 
added to drinking water causes colitis 
by this mechanism and has been 
used to identify a number of genes 
required for appropriate protection 
and reinforcement of the epithelial 
barrier. 
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Our intimate and complex 
relationship with the 1013–1014 bacteria 
that reside in our colons has been 
explored in animal models. Activation 
of Toll-like receptor (TLR) signaling by 
luminal commensals has been shown 
to provide cytoprotective signals to 
the host [17]. However, commensals 
can also trigger disease development, 
because in germ-free conditions mice 
with defective immune regulation 
do not develop colitis [18,19]. 
Interestingly, a recent paper showed 
that a colitogenic microbial community 
spontaneously developed in susceptible 
Rag2/T-Bet double knockout mice 
[20]. This microbial community could 
transmit colitis to wild-type mice, and 
colitis was effectively cured by broad-
spectrum oral antibiotics. Importantly, 
the animal models and analysis of 
immune responses in patients suggest 
that the immune response in IBD is 
largely directed against the luminal 
microbiota, rather than being a 
classical autoimmune disease. The 
presence of autoantibodies and 
extraintestinal symptoms in some 
patients are thus probably secondary to 
the intestinal inflammation. 
A hallmark of IBD is an increase 
in the level of pro-inflammatory 
cytokines. The best studied of these 
are tumor necrosis factor (TNF)-α 
and interferon (IFN)-γ, but animal 
experiments also identified IL-23 as a 
contributor to intestinal inflammation 
[2]. This cytokine is a heterodimer of 
p40 (encoded by IL-12B) and a unique 
p19 subunit and functions by driving 
and/or sustaining a Th17 response. 
Recently, Th17 cells have been 
documented in human IBD [21], and 
the central involvement of Th17 cells 
is further supported by recent genetic 
findings (see below).
Two recent publications in PLoS
Medicine shed new light on colitis 
development. Heazlewood et al. 
[4], in a model representative of 
reduced epithelial barrier, studied 
two independent noncomplementing 
strains of mutant mice that 
developed spontaneous colitis. Both 
strains had a missense mutation 
in the Muc2 gene. Mutant Muc2 
oligomerized inappropriately, causing 
an endoplasmic reticulum (ER) 
stress response in goblet cells with 
subsequent reduced mucus secretion 
and concomitant increase in lamina 
propria proinflammatory cytokines. 
Importantly, the authors found MUC2 
precursor accumulation and ER stress 
in human UC, even in noninflamed 
areas, suggesting that UC patients (at 
least some) have genetic alterations 
leading to ER stress and aberrant 
mucin assembly. 
Kang et al. [5], in a model 
representative of immune 
dysregulation, reasoned that genetic 
predisposition to IBD is caused by 
interaction of several genes, while 
gene-targeted mouse models rely on 
the absence of a single gene product. 
Thus, they generated a mouse line 
with defective IL-10 signaling as well 
as defective TGF-β signaling in T 
cells. Mice with defective signaling 
from both of these regulatory 
cytokines developed fulminant UC-
like disease that was ameliorated 
by anti-cytokine therapy: anti-IFN-γ 
particularly in combination with 
anti-TNF-α alleviated most aspects of 
pathology. Furthermore, colitis could 
be completely prevented by oral broad-
spectrum antibiotics, confirming an 
involvement of enteric bacteria in 
colitis development. 
Genetics of Human IBD 
The understanding of the genetics 
of human IBD is progressing with 
tremendous speed. NOD2 (CARD15)
was identified as a susceptibility gene 
in 2001 [22,23]. In 2007, genome-
wide association (GWA) studies were 
introduced [6]. This has led to the 
identification of a large number of 
new IBD genes, and additional genes 
are continuously being identified (see 
references within [7,8]). A recent 
meta-analysis reported on 32 CD 
genes and indicated that the actual 
number of CD genes is substantially 
higher [24]. With the exception of 
NOD2 (CARD15) and IL-23R, which 
each explain 1%–2% of the total 
genetic variance, the odd ratios of the 
other loci are low (generally <1.3), 
and their individual contribution to 
the genetic variance is meager. The 
32 loci were altogether estimated to 
account for about 10% of the overall 
variance in disease risk, which may 
be as much as a fifth of the genetic 
risk [6,25]. Although no extensive 
GWA study has been performed 
on UC yet, it has become clear that 
some of the identified genetic factors 
doi:10.1371/journal.pmed.0050198.g001
Figure 1. Mucosal Homeostasis in the Gut
Goblet cell-secreted mucus, Paneth cell-secreted antimicrobial peptides, and secretory 
immunoglobulin A (SIgA), generated from epithelial transport of dimeric IgA produced by lamina 
propria plasma cells (PC), cooperate to reinforce epithelial barrier function. Breach of this barrier 
causes excessive stimulation of the mucosal immune system by commensal bacteria and leads to 
pro-inflammatory T cell–mediated immune responses. Gene deficiencies in immune regulatory 
factors may also lead to intestinal inflammation. Commensal flora and bacterial products trigger 
antigen presenting cells (APC) to produce several cytokines including TNF-α, IL-23, and TGF-β, 
depending on context. Epithelial activation of the transcription factor NF-κB by bacterial products 
may enhance host resistance by reinforcing the epithelial barrier. A mixed Th1/Th17-driven 
inflammation is controlled by regulatory T cells (Treg) through suppressive cytokines (TGF-β and 
IL-10) and other mechanisms. Some key cytokines important for T helper cell differentiation or for 
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are shared between CD and UC, 
but also that some of the genetic 
factors are specific for either CD or 
UC (Table 1) [25,26]. In particular, 
it is striking that NOD2 (CARD15), 
which is an intracellular sensor of 
bacterial peptidoglycan, and ATG16L1
and IRGM, which are involved in 
autophagy, are genetic factors for 
CD, but not for UC. This indicates 
that there are distinct pathogenic 
mechanisms related to microbial 
processing in CD and UC. The 
identification of IL-23R and IL-12B as 
risk factors in both CD and UC points 
to common inflammatory pathways 
of the two disorders, and underscores 
the observations of mouse models that 
inflammation involving Th17 cells is 
important.
The new genetic findings have many 
implications. Most importantly, the 
identified susceptibility genes point at 
pathogenic pathways. These pathways 
also represent targets for therapy, 
which can either be the molecules 
encoded by the susceptibility genes 
themselves or other molecules 
involved in the same molecular 
pathways. 
Despite the recent success, the 
genetic studies of humans have several 
shortcomings. Novel and strong 
genetic factors can still be discovered, 
as GWA studies do not effectively 
address rare polymorphisms that 
may have high penetrance or copy 
number variation. As for the regions 
that have been discovered, it is often 
difficult to pinpoint the responsible 
gene and even more difficult to 
pinpoint the causative mutation, due 
to linkage disequilibrium. Animal 
models have the potential to assist 
in solving these problems, even 
though the background genes will 
be different and there are likely 
differences between the animal and 
human gut physiology. The function 
of the different genes suggested by the 
genetic studies can be tested in in vivo 
settings, and the function of particular 
polymorphisms can be tested by gene 
knock-in or other types of genetic 
manipulation. Such models have been 
developed in mouse for studies of the 
NOD2 gene.
Animal Models in the New Genetics 
Era: Lessons from NOD2
Individuals with mutations in the NOD2
gene leading to altered NOD2 protein 
have increased risk for ileal-only and 
ileocolonic CD, but not colonic-only 
CD nor UC. This risk is particularly 
high for homozygous or compound-
heterozygous individuals. NOD2 
activates an NF-κB signaling pathway 
upon binding the peptidoglycan 
component muramyl dipeptide. 
Two models of genetically 
manipulated mice have been 
developed to study the function of 
NOD2 in IBD [27,28]. In one model, 
NOD2 has been knocked out. In the 
absence of NOD2, TLR2 activation 
by peptidoglycan (or Pam3Cys) 
leads to excessive IL-12 production 
by macrophages, and thus a Th1 
polarizing environment, suggesting 
that the human NOD2 polymorphisms 
associated with CD are loss-of-function 
mutations. This result also suggests 
that there is inhibitory cross talk 
between different bacterial sensors. 
Furthermore, NOD2 transfection 
into epithelial cells enhanced their 
resistance to bacterial infection, and 
its expression in Paneth cells in vivo 
is required for expression of a subset 
of defensins, suggesting that loss-of-
function mutations reduce innate 
epithelial defense and therefore upset 
mucosal homeostasis. 
An alternative explanation for 
NOD2 involvement in CD has 
come from knock-in animals with 
a mutation equivalent to the most 
common human CD-associated allele, 
3020insC. Macrophages from these 
mice showed increased production of 
mature IL-1β upon muramyl dipeptide 
stimulation, suggested to be caused by 
a gain-of-function mutation in NOD2 
that activated caspase-1, an enzyme 
required for the activation step of IL-
1β. At the same time, macrophages 
from 3020insC knock-in mice retained 
Table 1. Genetic Associations in Crohn Disease and Ulcerative Colitis
Gene/Region/Locus Chromosomal Location Function
Genes common to CD and UC
IL-23R 1p31 IL-23 receptor. IL-23 induces IL-17, which promotes inflammation.
MST1 3p21 Involved in motile activity and phagocytosis by macrophages.
IBD5 (region with several candidate genes) 5q31 Not identified.
IL-12B 5q33 Common p40 subunit of IL-12 and IL-23.
HLA 6p21 Major histocompatibility complex. Important for antigen presentation.
TNFSF15 9q32 TNF-like factor expressed in endothelial cells, which can activate NF-κB.
CCNY 10p11 Unknown.
Gene desert  10q21 Not identified.
NKX2-3 10q24 Homeobox transcription factor involved in gut immune system development. 
STAT3 17q21 Signal transducer and activator of transcription 3, involved in signaling from various 
cytokine receptors, including IL-23R.
PTPN2 18p11 T cell protein tyrosine phosphatase, a negative regulator of inflammation.
Genes specific for CD
ATG16L1 2q37 Involved in autophagy. Autophagy eliminates intracellular pathogens and supports both 
innate and adaptive immunity. 
PTGER4 5p13 Prostaglandin E receptor 4.
IRGM 5q33 Involved in autophagy. 
NOD2 (CARD15) 16q12 Intracellular sensor of bacterial peptidoglycan involved in NF-κB activation.
Genes specific for UC
ECM1 1q21 Glycoprotein expressed in small and large intestine that activates NF-κB signaling.
For several regions it has not been unequivocally determined what the true disease-implicated gene is. This list is not complete, as new genes are continuously being 
identified. A more comprehensive list is found in [24].
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normal TLR signaling. Although work 
with engineered mice strains have 
provided mechanistic understanding of 
how NOD2 might work, these studies 
have not settled the debate on the 
mechanism by which NOD2 variants in 
human IBD enhance susceptibility to 
CD. Neither mouse model developed 
spontaneous IBD, so chemical irritation 
or antigen-driven UC-like models 
have been used, even though NOD2
mutations are linked to CD and not UC 
in humans. 
The Way Forward for Animal 
Models
The list of human IBD genes is 
continuously expanding. Some of the 
identified risk genes fit with pathways 
suggested by animal models, like the 
central role of Th17 cells. It will be 
interesting to see how many other 
genes will map to pathways that have 
been identified by animal models. 
Most of our current animal models 
have been developed without human 
genetics as a roadmap, but we can 
expect that this will change drastically. 
New models will be developed to 
understand the function of the novel 
IBD genes. The experience from 
studies of NOD2 in mice suggests that 
the development of adequate models 
will not be straightforward. Most 
of the novel gene polymorphisms 
are low-penetrance genes, and the 
development of suitable animal 
models for such genes can be 
particularly demanding. The intestinal 
physiology of the mouse and human 
gut are different, and the function 
of many genes can have species 
differences. Moreover, if there are 
gene–gene and gene–environment 
interactions for the risk genes, re-
establishing the context into which 
a gene is predisposing to IBD will be 
difficult. A major environmental factor 
is the composition of the luminal 
bacterial community. Although there 
are differences between human 
and test animal microbiota, and the 
host–bug interactions likely will be 
different, the Human Microbiome 
Project (US), MetaHIT (Europe), 
and other big science projects aimed 
at determining composition of 
gut microflora in humans and test 
animals will surely be useful to IBD 
researchers. A further challenge 
will be to develop models that are 
representative for CD or UC or the 
major phenotypes within. Despite 
these challenges, good animal 
models are badly needed to bring 
new therapies to the clinic. Animal 
models of IBD should hence receive 
a continued interest, not least from 
clinicians, in the future.  
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